Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Sep 07, 2022 3:43pm
273 Views
Post# 34947656

In a nutshell...

In a nutshell...The value of the underlying assets, namely...
  • PMX
  • EAA and
  • Dialco

are increasing rapidly ... and will continue to do so as ....
  • Tigris progresses (excrutiatingly) slowly but surely, with results that are "exceeding expectations"
  • the RWE continues to mount  (including hemoperfusion as a viable solution to the Sepsis and other immune over-response afflictions including possibly ARDS and Covid)
  • the EDEN Study broadens the future lablel
  • The FDA grants Breakthrough status (ie speeds up the endgame)
  • SAMI continues to land orders and begins to ship product (validating the technology of the Infomed equipment and dialysate bags)
  • the "key" DIMI useablity Trial partner is announced - indicating that an endgame for that peice is gettign closer

I see it as, although the SP is holding or rising (vs general markets), there is a growing gulf between Market Cap (sub $ 100M USD) and underlying value (climbing from $ X Billion to $ X Billion + $ 1B or $ 2B or 3B ...)


This gulf needs to be RESOLVED...especially as one or both of the Partners (the PMX one & Da Dialco one) step up, write cheques, and in so doing begin to show their hands.

The current gulf implies that the potential Buyers of the NA Rights are privy to/entitled to more information as to value..than are the general markets and minority shareholders (who look at SP to decide "value")...Value stems from the magnitude of future revenues and EBITDA calculations for all asset categories.  The gulf  between what potential buyers know and or are assuming, and what many shareholders do not, cannot be allowed to get out of hand...especially as and when capital is being raised.

Time to let'er rip !

MM
<< Previous
Bullboard Posts
Next >>